Epigenic Therapeutics Wins Third Prize at 2025 North America Biomedical Innovation Competition

This competition brings together the most promising biomedicine innovation forces from around the globe. After fierce competition in the preliminary and semi-final rounds, 17 start-up teams focusing on drug development, medical devices, diagnostic technologies, and other fields have advanced to the finals. The participating projects will be showcased through professional roadshows, evaluated based on dimensions such as technological innovation and clinical transformation potential. The judging panel of the competition consists of investment executives from top global institutions such as Roche, F Prime Capital, SOSV, Kendall Capital Partners (KCP), PagodaTree Partners, Eisai Innovation, and Hong Kong Science and Technology Parks (HKSTP), aiming to identify early-stage biomedicine projects with a global perspective and commercialization potential.

Epigenic Therapeutics, Inc. focuses on the development of innovative therapies in the field of epigenetics, committed to addressing unmet clinical needs through gene regulation technology. This award not only recognizes the company's scientific research capabilities and commercial prospects but also highlights Epigenic’s leading position in the global biopharmaceutical innovation wave.

The finals were held on June 14 at the Simcere Pharmaceutical Boston Innovation Center, combining offline invitations with online live streaming, drawing widespread attention from global investment institutions and industry audiences. Winning projects from the previous three editions of the competition have collectively secured over 100 million US dollars in financing. Epigenic's successful shortlisting signifies an even broader development space for its future capital and industry cooperation.

Dr. BaoHong Zhang, co-founder and CEO of Epigenic Therapeutics, Inc., said: "We are very honored to be recognized on this international stage. In the future, we will continue to focus on the field of epigenetics, accelerate the development of innovative therapies, and bring more efficient and precise treatment options to patients worldwide."

Shanghai FT1 Life Science Park (Abbreviation"Simbay Park, StarNorth · Free Trade Zone No.1") is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the StarNorth Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "FTAs + bonded" outward-oriented economic regional advantages. By gathering the entire industry chain service resources of CRO+CDMO+CSO+EHS in biopharmaceuticals, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, it provides enterprises with truly in-depth technical incubation in the medical industry and becomes a steward for the transformation of corporate technology achievements, striving to build an international biopharmaceutical industry innovation and entrepreneurship base.